Art Levin trades the C-suite for pair of roles at Avidity; Ex-Merck CEO Ken Frazier to chair another company
→ Art Levin is calling it a day as CSO of Avidity Biosciences, but he’s not going anywhere: He’s been given the title of “distinguished scientist and strategic leader” and will join the board of directors. Chief technical officer Michael Flanagan will be elevated to chief scientific and technical officer.
Levin, Flanagan and CEO Sarah Boyce spoke to Endpoints News in December about early-stage data for Avidity’s siRNA therapy in myotonic dystrophy type 1, AOC 1001. The FDA issued a partial clinical hold on the drug less than two months earlier, citing a serious adverse event. Avidity has the distinction of owning the ticker $RNA and shares skyrocketed more than 80% after the data were released.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.